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nisms. The objective of the present study was to conﬁrm
the existence of this psychological adaptation capacity 
in chronic patients as kidney transplant bearers.
METHODS: We studied the Erectile Dysfunction (ED)
using the IIEF-5, and the HRQOL, using the SF-36
Health Survey, in all renal transplant patients of our
region (n = 242), searching for the inﬂuence of ED over
the HRQOL of these patients. RESULTS: Included
patients = 199 (82%); Excluded patients = 44. Median
age was 52yrs. (43–62); 106 patients (54.9%) presented
ED measured by a IIEF-5 score =<21 points. Severity of
ED was as follows: severe ED = 20.7%, moderate ED =
10.9%, mild to moderate ED = 11,4%, mild ED = 11.9%
and no ED = 45.1%. These patients were separated into
4 groups according to median age and quartiles: =<42
years (group1); 43 to 51 (group2); 52 to 61 (group3); and
>= 62 (group4). SF-36 scores were worse for ED patients
in the 3 ﬁrst age groups, but not in the aged group 4.
These differences between patients with ED and patients
without ED were statistically signiﬁcant in age groups 2
and 3, mainly in physical areas: Group 1, Bodily Pain;
Group 2, General Health and Physical Component
Summary score (PCS); Group 3, Rol Physical, Vitality and
PCS. SF-36 Mental Component Summary (MCS) was
similar for patients with ED and patients without ED in
all age groups. CONCLUSIONS: Opposite to commonly
accepted, we conﬁrmed the hypothesis that a mental
adaptation occurs in chronic patients as the studied 
subjects. Association found of ED with PCS and other
dimensions of physical area could be explained with the
intermediate inﬂuence of other variables.
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OBJECTIVE: The objective was to combine, in one,
paper-based, self-completion instrument, the strengths of
two approaches to assessing health-related quality of life:
the sensitivity and relevance of the disease-speciﬁc
approach and the generalizability and decision support
power of the utility approach. The instrument was devel-
oped for erectile dysfunction (ED). METHODS: The
instrument has two linked stages, each with a visual
analog scale (VAS). VAS1 measures preferences for the
patient’s self state and for disease marker states. VAS2
measures preferences on the traditional dead-healthy 0–1
scale. The instrument was used in a double-blind,
placebo-controlled, 12-week clinical trial (n = 169). At
subject recruitment, it was administered twice, one week
apart. All results reported here are based on that data,
except responsiveness, which is based on the 12-week
data for both treatment groups combined. RESULTS:
Feasibility: Completion rates were approximately 90%
overall and approximately 95% for key data. Error rates
were 2%. Most patients required minimal or no assis-
tance. Reliability: One-week, test-retest reliabilities of all
preference scores, as measured by intra-class correlation,
were strong (>0.50). The key score, self-state on VAS2,
had the highest reliability (0.70). Face validity: Scores
were ranked in the expected order. Discriminative 
validity: Self-state scores were positively and statistically
signiﬁcantly correlated with disease severity. Pearson cor-
relation coefﬁcients were 0.37 on VAS1, 0.24 on VAS2.
Responsiveness: Change over 12 weeks in self-state scores
were positively and statistically signiﬁcantly correlated
with change in disease severity. Spearman correlation
coefﬁcients were 0.44 on VAS1, 0.37 on VAS2. CON-
CLUSIONS: We have developed a preference-based,
disease-speciﬁc instrument for ED. The instrument pro-
vides preference scores for the patient’s self state and for
clinical marker states on a disease-speciﬁc scale and on
the traditional 0–1 dead-healthy generic scale. The per-
formance of the instrument in this initial application 
was encouraging. The instrument demonstrated feasibil-
ity, reliability, validity and responsiveness.
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OBJECTIVES: Estro-progestinic substitutive therapy
(HRT) showed to increase breast cancer incidence, if the
therapy is prolonged over ﬁve years, and cardiovascular
events in some subsets of patients (HERS trial), never-
theless it protects against colon cancer and osteoporosis.
Thrombophilia might mediate the adverse cardiovascular
effect of HRT. METHODS: We used a parametric
Markov model to shape health states and events (breast
cancer, colon cancer, venous thromboembolism, biliary
cholic, bone fractures, myocardial infarction). Quality of
life depended on both the modeled health states/events,
but also on menopause symptoms. Decision analysis
(DATA 4.0, TreeAge) assessed the impact of screening for
unknown thrombophilia (factor V Leiden, prothrombin
G20210A, hyperhomocysteinaemia) on life expectancy
(LE) and quality-adjusted life expectany (QALE).
RESULTS: Screening for thrombophilia all the post-
menopausal women does not lead to an increment of
QALE, that remains 28.05 quality-adjusted life years
(QALYs). However, screening is warranted in hyperten-
sive women since those who carry either the prothrom-
bin mutated gene or two Leiden mutated factor V genes
do better to avert HRT since this allows the population
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to gain 0.5 QALYs. Screening is warranted in hyperten-
sive women despite a high predisposition to breast cancer:
the overall gain of screening in this subset is 0.8 QALYs.
Those women who carry both factor V and prothrombin
mutations should stop HRT after 4.2 years. Multiple-
ways sensitivity analysis showed that in women with 
no thrombophilia the risk of coronary disease or breast
cancer do not inﬂuence the utility of HRT, while the risks
are fundamental in deciding whether to treat women with
multiple thrombophilic defects. Thus, family and per-
sonal history and post-menopausal symptoms do not
deﬁne a risk proﬁle that can really optimize HRT pre-
scription in all the patient subsets. CONCLUSIONS:
According to the available evidence, screening for throm-
bophilia is not helpful in all candidates for HRT, however,
speciﬁc risk proﬁles should prompt the screening as to
allow for a speciﬁc optimization of HRT prescription and
duration.
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OBJECTIVES: Determine the value of the Puregon Pen
compared to the standard syringe treatment for women
undergoing infertility treatment. METHODS: A discrete
choice experiment (DCE) was developed and piloted on
18 women experienced with gonadotrophin injections
with the standard syringe. Based upon responses, the
instrument was revised and after obtaining informed
consent, administered by nurses to a convenience sample
of 60 women with 1 or 2 prior cycles of injected
gonadotrophins for infertility treatment in 6 participating
clinics in France. Attributes in the DCE were “local skin
reactions” and “cost”. Based on these attributes respon-
dents were asked to choose between “continuing with the
syringe” or “switching to the Pen”. The experiment used
an orthogonal in difference design and each subject was
presented with 15 choices. Given cost was included as an
attribute willingness to pay for both the syringe and pen
could be estimated. Information was also collected on
demographics and pain, anxiety and fear of syringe injec-
tions. RESULTS: There were 50 evaluable respondents.
Average age was 33; 69% had 1 previous cycle of infer-
tility treatment, 62% had injections at home by a nurse
and 18% self-injected. 29% indicated the injections were
always or usually painful and 62% feared the injection
would not be done properly if self-injected. The discrete
model analysis indicated a general preference for the Pen
over the syringe and a WTP of €56. CONCLUSION:
Women were capable of choosing between the Pen and
syringe and from this WTP for the different treatment
options was estimated. Based on these results, women
prefer the Pen over the syringe.
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OBJECTIVE: Several studies have presented conﬂicting
reports concerning the relationship between paternal
organic solvent exposure and spontaneous abortions
(SAs). We conducted a meta-analysis to evaluate and
quantify that risk. METHODS: A literature search was
performed on Medline, Toxline, and Embase. We
searched for all original comparative research studies,
published from 1966 to the present (AP 2002), that inves-
tigated pre- and periconceptional paternal organic solvent
exposure and subsequent SA. Two independent reviewers
identiﬁed and extracted the data; disagreements were
resolved by consensus. The Mantel-Haenszel method was
used to calculate summary odds ratios (ORs) with 95%
conﬁdence intervals (CI). Homogeneity of effects was
assessed using chi-square and a funnel plot was used to
examine publication bias. RESULTS: Forty-four studies
were identiﬁed; 39 were excluded (13 examined inappro-
priate exposures, 12 had inappropriate outcomes, 9 were
reviews, 4 had no extractable data, 1 was a duplicate).
Five studies provided useable data, but the exposure
assessment varied considerably. Some studies used only
occupational codes, while others conducted telephone
interviews to insure actual exposure. For the 3 case
control studies with conﬁrmed high exposure to solvents
(n = 91,550), ORs = 1.26(CI 95%: 0.80–1.99). Power
was 87.8%. When all available data (n = 18,800) were
combined, ORs = 1.19 (CI 95%: 1.04–1.35), but effects
were heterogeneous (Chi-square = 56.74, p < 0.001) and
the funnel plot displayed publication bias, as there were
no small negative studies. After adjusting for bias, signif-
icance disappeared (ORs = 0.98, 0.90–1.08). CONCLU-
SION: The risk for spontaneous abortion is not increased
by the paternal occupational exposure to organic sol-
vents. Selective publication of small positive studies may
have falsely exaggerated this risk.
